It's funny how Solantey/WCoastGuy posts Lincoln Pa
Post# of 30028
Posted On: 08/01/2014 5:28:01 PM
It's funny how Solantey/WCoastGuy posts Lincoln Park Capital is still obligated to purchase an additional approximately $18,000,000 worth of shares, but fails to mention that the funding agreement gives Amarantus full discretion over whether to draw on the available funds or not. He's painting the picture that Amarantus is required to draw all remaining funds, and that's simply not true. As Gerald has stated, the funding agreement gives Amarantus bargaining strength in ongoing negotiations.
We all know there's a LymPro partnership agreement looming and that will likely include up-front payment in the tens of millions of dollar range, and with LymPro revenue generation following the CLIA launch it is unlikely Amarnatus will need to tap the line of credit with LPC. Further dilution is either minimized or eliminated at that point. Anyone who has followed the Amarantus story knows this. He's playing on the ignorance of new investors and those who do little or no DD of their own.
I'm glad to see his half truths and misinformation posts are no longer a part of this board. The outlandish pumping was just as bad as the ridiculous dilution scenarios now being described. Would love to see his name added to the banned list along with joboggi. Ouch! LOL
On a positive note, the 10-Q filing deadline is Aug 14, and there will be an investor conference call associated with this filing. Also, Gerald intends to outline the LymPro commercialization plan and revenue projects during that call, and I expect we'll see press releases the same day describing these in detail.
We all know there's a LymPro partnership agreement looming and that will likely include up-front payment in the tens of millions of dollar range, and with LymPro revenue generation following the CLIA launch it is unlikely Amarnatus will need to tap the line of credit with LPC. Further dilution is either minimized or eliminated at that point. Anyone who has followed the Amarantus story knows this. He's playing on the ignorance of new investors and those who do little or no DD of their own.
I'm glad to see his half truths and misinformation posts are no longer a part of this board. The outlandish pumping was just as bad as the ridiculous dilution scenarios now being described. Would love to see his name added to the banned list along with joboggi. Ouch! LOL
On a positive note, the 10-Q filing deadline is Aug 14, and there will be an investor conference call associated with this filing. Also, Gerald intends to outline the LymPro commercialization plan and revenue projects during that call, and I expect we'll see press releases the same day describing these in detail.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼